Get Live Data

The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Sareum Share Price
  4. Sareum Share News
  5. Sareum inches closer to drug breakthrough

Pin to quick picksSareum Share News (SAR)

Sareum Information

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.25
Bid: 24.00
Ask: 24.50
Change: -0.25 (-1.02%)
Spread: 0.50 (2.083%)
Open: 24.50
High: 24.50
Low: 24.00
Prev. Close: 24.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sareum inches closer to drug breakthrough

Wed, 24th Feb 2016 12:25

(ShareCast News) - Sareum Holdings was still running on the smell of an oily rag in its interim report on Wednesday, but the company was confident it was heading towards a breakthrough in its durgs under development.The AIM-traded cancer drug discovery and development business saw no revenue during the six month period, though it had £45,000 of other operating income.Its operating expenses grew 18.8% during the period to £449,000, though its share of losses of its associates shrunk 35.8% to £167,000.Sareum made a loss on its ordinary activities of £485,000, which was down 26.4% and in line with expectations."We have made considerable progress in the last six months," said CEO Dr Tim Mitchell."With clinical trials for the CHK1 programme expected to start before our financial year end, we are swiftly moving towards our goal of becoming a clinical-stage development company," he added.Operational highlights during the period included the completion of preclinical studies for the CHK1 candidate, in preparation for two planned clinical trials in cancer patients.The company published a description of CCT245737, the CKH1 clinical development candidate, in the high-impact Oncotarget journal.Sareum said US and Europe patents were granted for discoveries that underpinned the Aurora+FLT3 Kinase Inhibitors programme.It also demonstrated an effective reduction of symptoms when the TYK2 lead molecule was administered in a disease model of rheumatoid arthritis.At period end, cash in the company's bank was £335,000, down from £429,000, and the company's unspent investment in the CKH1 project was £841,000, up from £447,000 a year earlier.Post period end, Sareum submitted its application for CKH1 clinical trials, triggering a £200,000 milestone payment to the company.
More News
31 May 2018 12:17

Sareum Regains Worldwide Rights To Leukaemia Treatment

LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said

Read more
15 Mar 2018 13:55

Sareum Partner Sierra Oncology To Present Positive SRA737 Results

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of

Read more
9 Jan 2017 16:39

Sareum Holdings receives milestone payment

(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN

Read more
9 Jan 2017 12:19

Sareum To Receive USD550,000 From Joint Licence Success Payment

Read more
24 Oct 2016 15:02

Sareum reports positive results from TYK2 programme

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i

Read more
24 Oct 2016 08:13

Sareum Welcomes Positive Feasibility Results For Leukemia Treatment

Read more
17 Oct 2016 14:16

Sareum Holdings granted patents in Japan and Singapore

(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai

Read more
27 Sep 2016 11:13

Sareum Holdings Co-Investment Partner Inks Licence Agreement

Read more
3 Aug 2016 14:56

Sareum programme receives patents in Hong Kong and China

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito

Read more
23 May 2016 11:06

Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
23 May 2016 11:01

*Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
17 May 2016 08:03

Sareum Appoints Silence Therapeutics' Stephen Parker As Chairman

Read more
5 Apr 2016 12:33

Sareum cancer drug candidate gets MHRA trial approval

(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra

Read more
5 Apr 2016 09:46

Sareum Holdings Gets Clinical Trial Approval For Cancer Drug Candidate

Read more
24 Mar 2016 12:03

Sareum Raises GBP1.1 Million For Drug Development Programmes (ALLISS)

Read more
45678910111213

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.